Clinical Trial Update: Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

View source ↗

Summary

Clinical trial update examining resistance mechanisms to crizotinib and real-world pharmacoeconomics in patients with metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)

Snippet

Sponsor: Jewish General Hospital | Conditions: Non-small Cell Lung Cancer Metastatic | Status: UNKNOWN